EXAI - Exscientia's AI-Powered Drug Discovery Platform Is The Future Of Precision Medicine

2023-05-18 01:44:16 ET

Summary

• Exscientia's AI-driven drug discovery platform has positioned the company at the forefront of precision medicine, revolutionizing the way new therapies are developed.
• Exscientia's pipeline has precision oncology programs, such as EXS74539 and EXS73565, along with the initiation of Phase 1/2 trials for A2A receptor antagonist EXS21546.
• The company's recent press release highlights significant milestones, including strategic collaborations with industry leaders like Sanofi and Bristol Myers Squibb, signaling widespread recognition of Exscientia's innovative approach.

In the fast-paced world of pharmaceutical innovation, Exscientia plc (EXAI) has emerged as a trailblazer, revolutionizing the drug discovery process through the power of artificial intelligence. With a relentless commitment to harnessing the potential of AI algorithms, Exscientia is propelling the industry into a new era of precision medicine. By combining cutting-edge technology with a deep understanding of disease biology, Exscientia is redefining how drugs are developed and bringing hope to patients worldwide.

Exscientia's unique approach to drug discovery sets it apart from traditional pharmaceutical companies, providing an exciting investment opportunity in the healthcare sector. The company's AI-driven platform enables a highly efficient and accelerated drug discovery process, significantly reducing time and costs associated with traditional methods. This transformative technology not only enhances Exscientia's productivity but also positions the company to unlock the immense potential of precision medicine.

Financials Continue To Impress

Starting with revenue, Exscientia reported recognized revenue of $8.2 million for the three months ended December 31, 2022, and $32.9 million for the full year. While this represents an increase compared to the same periods in 2021, when the revenue stood at $5.0 million and $33.0 million, respectively, it's important to note that the year-over-year growth has been modest.

One of the key drivers behind Exscientia's financials is its research and development (R&D) expenses. In the three months ended December 31, 2022, R&D expenses amounted to $43.0 million, and for the full year, they reached $155.6 million. These figures mark a significant increase compared to the respective periods in 2021, when R&D expenses were $22.6 million and $53.2 million, respectively. The rise in R&D expenses can be attributed to the expansion of Exscientia's internal and co-owned portfolio, as well as the company's efforts to invest in technology and expand its workforce. However, it's worth noting that share-based compensation also played a role in the increase, accounting for $26.2 million in 2022 compared to $7.8 million in 2021.

General and administrative (G&A) expenses for the three months ended December 31, 2022, were $9.9 million, representing 15.4% of total operating expenses. For the full year, G&A expenses amounted to $46.4 million, accounting for 19.2% of total operating expenses. The increase in G&A expenses compared to 2021 primarily stems from higher personnel costs. It's important to closely monitor G&A expenses to ensure they are effectively managed, as they can impact the company's overall profitability.

In terms of cash inflows, Exscientia experienced growth in its collaborations, receiving $117.8 million in cash inflows for the full year 2022, compared to $85.3 million in 2021. This indicates a positive trend in the company's ability to attract partnerships and generate revenue through its collaborations.

Analyzing the net operating cash flow, Exscientia reported net operating cash outflows of $73.1 million for the full year 2022, in contrast to net operating cash inflows of $8.1 million in 2021. The increase in cash outflows reflects the company's significant investment in its pipeline and platform. However, it's worth noting that Exscientia ended the year with a cash balance of $610.9 million, compared to $678.9 million at the end of 2021, indicating a decrease in cash reserves. This reduction can be partially attributed to the negative foreign exchange impact of 12% on the company's USD holdings.

Despite the decrease in cash reserves, it's important to consider Exscientia's strategic approach to managing its deposits in both GBP and USD. This strategy helps the company match its operational cash needs and mitigate the impact of exchange rate fluctuations , which can provide stability in the long run.

Unique AI Products

Within its internal pipeline , Exscientia has generated various promising projects. Among these is EXS74539, a reversible, brain-permeable inhibitor of LSD1. This compound is being crafted to target LSD1 for potential oncology and hematology patients, including those with small-cell lung cancer (SCLC). Another project, EXS73565, involves an allosteric MALT1 protease inhibitor, though specifics about its mode of action and intended indications remain undisclosed. Moreover, Exscientia has launched a Phase 1/2 trial of their A2A receptor (A2AR) antagonist , EXS21546, alongside a PD-1 inhibitor for individuals with relapsed/refractory renal cell carcinoma ((RCC)) and non-small cell lung cancer (NSCLC). The AI-created immuno-oncology candidate has demonstrated encouraging outcomes in preclinical studies and will undergo assessment for its effectiveness and safety in patients during the ongoing IGNITE trial . Another project, GTAEXS617 , a CDK7 inhibitor, is anticipated to commence Phase 1/2 trials in the first half of 2023.

Besides their in-house projects, Exscientia has joined forces with Bristol Myers Squibb ( BMY ) on EXS4318 , a potent and selective PKC-theta inhibitor. Bristol Myers Squibb will manage the clinical and commercial advancement of EXS4318, while Exscientia stands to gain milestone payments and royalties on net product sales if approved.

Exscientia has also established partnerships with top medical institutions, such as Charité – Universitätsmedizin Berlin , to apply their functional drug testing platform to hematological cancers. This partnership seeks to harness Exscientia's proficiency and technology to further research in this area.

To bolster their precision medicine efforts, Exscientia has broadened its capacities by opening a cutting-edge laboratory in Vienna, Austria. This lab incorporates intricate multi-omics and functional data into their AI-guided platform, striving to enhance clinical success via improved preclinical models. They employ next-generation sequencing ((NGS)), a multi-omics platform, and precision medicine capabilities to deepen their understanding of disease function and identify clinically pertinent targets during the discovery phase.

Impressive Findings From AACR 2023

Exscientia has recently announced its participation in the American Association for Cancer Research (AACR) Annual Meeting 2023, where it will present four posters showcasing its groundbreaking research and innovative approaches in precision medicine and oncology. These presentations demonstrate Exscientia's commitment to integrating cutting-edge AI technology with exceptional scientific expertise to design novel molecules and identify the right patients for targeted therapies.

One of the posters unveils Exscientia's internally developed adenosine burden score ((ABS)) based on B-cell biology. The ABS is shown to be inversely correlated with PD-1 expression pathways, indicating that patients with high ABS are less likely to respond to checkpoint inhibitors. This finding highlights the potential of Exscientia's selective A2AR antagonist, EXS21546, in reversing the effects of adenosine analogues in patient tissue samples, positioning it as a promising candidate for personalized cancer treatment.

Another poster focuses on Exscientia's precision-designed LSD1 inhibitor, EXS74539. This reversible inhibitor offers advantages over other LSD1 inhibitors by combining reversibility and brain penetrance, potentially addressing dose-limiting thrombocytopenia observed with other compounds. By identifying genetic fingerprints that may serve as markers of sensitivity to EXS74539, Exscientia aims to optimize its efficacy and improve patient outcomes, particularly in small-cell lung cancer.

The third poster showcases Exscientia's use of its precision medicine platform and proprietary methodology for multi-omics data mapping. By integrating various datasets, including single-cell functional responses and known drug-to-target interaction landscapes, Exscientia aims to uncover novel targetable pathways in high grade serous ovarian cancer (HGSOC). The identification of the PI3K/AKT/mTOR pathway as a potential anticancer node and the exploration of the TNF-induced apoptosis function via the NF-?B pathway highlight the company's innovative approach to target discovery.

Lastly, Exscientia shares findings from the initial human trial of EXS21546, now advancing to Phase 1/2 clinical trials in individuals with recurring or resistant renal cell carcinoma ((RCC)) and non-small cell lung cancer (NSCLC). This research successfully met the objectives of Phase 1, establishing the pharmacokinetic and pharmacodynamic profiles, as well as the safety and tolerability of EXS21546 in a group of healthy participants. The ongoing IGNITE Phase 1/2 trial aims to evaluate the anti-tumoral effect of EXS21546 in combination with a PD-1 inhibitor, providing valuable clinical data to support Exscientia's patient enrichment biomarker strategy. By using the ABS to identify patients with adenosine-rich tumor microenvironments, Exscientia aims to select the right patients for targeted treatment, potentially enhancing therapeutic outcomes.

Potential Downfalls

EXS21546 aims to enhance anti-tumor immune responses and potentially improve the efficacy of cancer treatments, specifically in renal cell carcinoma and non-small cell lung cancer (NSCLC). However, a concern with A2A receptor blockade is the development of adverse effects associated with the inhibition of this receptor. The A2A receptor is involved in regulating cardiovascular function and the immune system, so selective inhibition by '546 could lead to unintended side effects or immune dysregulation. Additionally, patient response rates may vary, making it challenging to identify individuals who would benefit most from A2A receptor antagonism.

EXS74539 is an inhibitor of LSD1, which plays a role in gene regulation and epigenetic modifications. By inhibiting LSD1, EXS74539 aims to modulate gene expression and potentially interfere with tumor growth, particularly in small-cell lung cancer (SCLC). However, a concern with LSD1 inhibitors is the potential for off-target effects . LSD1 is involved in various cellular processes, and inhibiting it could disrupt normal gene regulation in healthy cells, leading to unintended consequences. Moreover, the reversible nature of EXS74539's LSD1 inhibition may pose challenges in achieving sustained and desirable therapeutic effects, as the compound may be rapidly eliminated from the body or exhibit variable efficacy across different patients.

In addition to specific drug candidates, Exscientia's precision medicine platform for target discovery combines multi-omics data and functional analyses to identify targetable pathways in diseases such as ovarian cancer. While this approach holds promise, challenges may arise in accurately interpreting complex multi-omics data and translating it into clinically relevant targets. The identification and validation of suitable biomarkers and targetable pathways can be complex and require extensive validation in clinical settings. Furthermore, the discovery of novel targets may raise questions about the availability of appropriate drugs or therapies to effectively target these pathways.

Competitive Advantages

In the case of EXS21546, Exscientia's product stands out due to its AI-driven design and selective action. The use of artificial intelligence enables the precise optimization of EXS21546, resulting in a molecule with enhanced affinity and specificity for the A2A receptor. This selectivity is crucial in minimizing off-target effects and reducing the potential for adverse reactions. Additionally, Exscientia's EXS21546 has shown the ability to revert the effects of adenosine analogues ex vivo, indicating its potential to counteract immunosuppression within the tumor microenvironment. This unique mechanism of action sets EXS21546 apart from competitors and enhances its potential to improve anti-tumor immune responses.

In the case of EXS74539, this product demonstrates advantages in its design and reversible mechanism of action. Unlike traditional irreversible inhibitors, EXS74539's reversibility offers potential benefits in terms of safety and dosage optimization. Irreversible LSD1 inhibitors have been associated with dose-limiting thrombocytopenia, which may restrict their clinical application. In contrast, Exscientia's reversible LSD1 inhibitor may provide a better safety profile by allowing for precise modulation of LSD1 activity without permanently inhibiting the enzyme. This reversibility can potentially minimize side effects while maintaining therapeutic efficacy. Additionally, EXS74539 exhibits brain penetrance, enabling it to target LSD1 in the central nervous system, which is particularly relevant for diseases such as small-cell lung cancer that often metastasize to the brain.

Exscientia's competitive advantage is further bolstered by its AI-driven platform and precision medicine approach. By leveraging artificial intelligence and machine learning algorithms, Exscientia can rapidly and efficiently design novel drug candidates, accelerating the drug discovery process. The integration of multi-omics data and functional analyses within Exscientia's precision medicine platform enhances target discovery and the identification of potential biomarkers. This comprehensive approach allows for a more thorough understanding of disease biology, facilitating the development of personalized and targeted therapies.

Conclusion

In conclusion, Exscientia is poised for a bright financial future fueled by its innovative approach to AI-driven drug discovery. The company's recent achievements, including strategic collaborations with industry giants and a robust pipeline of precision oncology programs, demonstrate its strong position in the pharmaceutical landscape. With its unique platform, Exscientia has successfully harnessed the power of artificial intelligence and machine learning to revolutionize the drug development process, delivering faster and more efficient results.

The impressive financial results, marked by significant revenue growth and substantial cash inflows from collaborations, underscore the market's confidence in Exscientia's disruptive technology. These positive financial indicators reflect the company's ability to attract strategic partnerships and establish itself as a leader in the field of precision medicine.

For further details see: